| Field | Specification |
|---|---|
| Target | |
| Alternative names | Nibrin; Cell cycle regulatory protein p95; Nijmegen breakage syndrome protein 1; hNbs1; NBN; NBS; NBS1; P95 |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human p95 NBS1, different from the related mouse sequence by three amino acids, and from the related rat sequence by five amino acids. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone 5D7A1 is a mouse monoclonal antibody that recognizes nibrin (gene NBN) in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF and flow cytometry. The predicted molecular weight is 85.0 kDa, and the supplier reports an observed band at about 95 kDa.
Nibrin (NBN, NBS1) is a component of the MRE11-RAD50-NBN (MRN) complex, which detects DNA double-strand breaks and recruits and activates ATM. MRN starts end resection for homologous recombination and supports checkpoint signaling and telomere maintenance. NBN mutations cause Nijmegen breakage syndrome.
| Target | Nibrin (gene NBN; UniProt O60934, human) |
|---|---|
| Clone | 5D7A1 |
| Host / Clonality / Isotype | Mouse / Monoclonal / Mouse IgG2a |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 85.0 kDa |
| Observed MW | 95 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1x6 cells (Human) |
Samples with a confirmed band (WB): human Jurkat cells, human A549 cells, rat brain tissue, rat testis tissue, mouse brain tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human testis cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): A431 cells.
Samples with a confirmed signal (flow cytometry): A431 cells.
Immunogen
Synthetic peptide from the C-terminal region of human p95 NBS1. It differs from the mouse sequence at three residues and from the rat sequence at five residues.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places nibrin in the nucleus and chromosome. Tissue expression noted by UniProt (human): Ubiquitous. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
